中药治疗非酒精性脂肪性肝纤维化的研究现状

南月敏; 李文聪

中药治疗非酒精性脂肪性肝纤维化的研究现状

河北医科大学第三医院中西医结合肝病科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 3307
- HTML全文浏览量: 17
- PDF下载量: 745
- 被引次数: 0
出版历程
- 出版日期: 2013-04-20

Traditional Chinese medicines for treatment of non-alcoholic fibrosing steatohepatitis

摘要

摘要:
非酒精性脂肪性肝纤维化是非酒精性脂肪性肝炎(NASH)进展为终末期肝病的关键病理阶段,其有效治疗亟待解决。中药具有多组分及多途径、多靶点作用的特点,对非酒精性脂肪性肝纤维化具有综合治疗的优势,可通过调节肝脏脂质代谢、抑制氧化应激反应及肝细胞凋亡、调节炎症、纤维化相关基因的表达等阻止肝脂肪变、炎症及纤维化的发生与进展。
- 脂肪肝 /
- 肝硬化 /
- 中草药
Abstract:
The incidence of non-alcoholic fatty liver disease (NAFLD) continues to rise globally.Later stages of NAFLD are characterized by severe structural and functional perturbations in the liver, with the progressive clinical manifestations being fibrosis and cirrhosis, leading to end-stage liver disease.Thus, the pathogenic process of hepatic fibrosis has been a principal target of efforts to develop therapeutic interventions capable of suppressing NAFLD progression, with the aim of protecting liver function and ultimately promoting patient quality of life and survival.Extensive research has uncovered several of the molecular factors and signaling pathways leading to the excessive synthesis and deposition of extracellular matrix (ECM) or collagen, including those of inflammation, oxidative stress and apoptosis.In this review, we discuss the potential of traditional Chinese medicine (TCM) herbs for inhibiting or resolving fibrosis by interacting with the various underlying mechanisms.In particular, the Fuzheng Huayu recipe (FZHY) is comprehensively discussed, from its various reported effects on liver function enzymes and ECM-/cytokine-producing cells to lipid metabolism.In addition, other promising TCM agents and strategies are discussed from the perspective of their therapeutic effects studied and demonstrated in cell culture systems, animal models and human clinical studies.
- fatty liver /
- liver cirrhosis /
- drugs

HTML全文

参考文献(27)

[1]Liu M, Kong XX, Yang P, et al.Effect of fibroblast growthfactor-21 on lipid metabolism of nonalcoholic fatty liver dis-ease cell model induced in vitro[J].J Jilin Univ (Med Edit) , 2012, 38 (3) :477-481. (in Chinese) 刘敏, 孔祥鑫, 杨苹, 等.成纤维细胞生长因子-21对体外诱导的非酒精性脂肪肝细胞模型脂代谢的影响[J].吉林大学学报 (医学版) , 2012, 38 (3) :477-481.

[2]Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis andmanagement of non-alcoholic fatty liver disease:practiceguideline by the American Association for the Study of LiverDiseases, American College of Gastroenterology, and the A-merican Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.

[3]Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, et al.Non-alcoholic fatty liver disease-new view[J].PolMerkur Lekarski, 2008, 24 (144) :568-571.

[4]Liu CH, Liu P, Hu YY, et al.Progress of clinical and basic re-search on liver fibrosis with traditional chinese medicine[J].World Sci Technol-Mod Traditi Chin Med, 2007, 9 (2) :112-119. (in Chinese) 刘成海, 刘平, 胡义扬, 等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术-中医药现代化, 2007, 9 (2) :112-119.

[5]Nan YM.Advance in pathogenesis of non-alcoholic fatty liv-er disease[J].Mod Digest Inervent, 2009, 14 (3) :169-172. (in Chinese) 南月敏.非酒精性脂肪性肝病发病机制的研究进展[J].现代消化及介入诊疗, 2009, 14 (3) :169-172.

[6]Jiao XF, Jiang SS, Han YM.Progress of tradition Chinesemedicine and pharmacy on nonalcoholic fatty liver diseases[J].Hunan J Traditi Chin Med, 2007, 23 (1) :86-88. (inChinese) 焦希斐, 蒋士生, 韩育明.非酒精性脂肪性肝病的中医药研究进展[J].湖南中医杂志, 2007, 23 (1) :86-88.

[7]Liu P, Wu DZ, Liu CH, et al.Mechanism study on combina-tion of chinese herbal formula to support anti-pathogenic a-bility and dissipate blood stasis in promoting reversion of liverfibrosis in CCI4 rats[J].Acta Univ Traditi Med Sin Pharma-col Shanghai, 2002, 16 (1) :37-41. (in Chinese) 刘平, 吴定中, 刘成海, 等.扶正化瘀中药复方促进CCl4大鼠肝纤维化逆转的配伍机理研究[J].上海中医药大学学报, 2002, 16 (1) :37-41.

[8]Jia YH, Wang RQ, Mi HM, et al.Fuzheng Huayu recipe pre-vents nutritional fibrosing steatohepatitis in mice[J].LipidsHealth Dis, 2012, 11 (1) :45.

[9]Wang QL, Tao YY, Shen L, et al.Chinese herbal medicineFuzheng Huayu recipe inhibits liver fibrosis by mediating thetransforming growth factor-β1/Smads signaling pathway[J].J Chin Integr Med, 2012, 10 (5) :561-568. (in Chi-nese) .王清兰, 陶艳艳, 沈丽, 等.扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J].中西医结合学报, 2012, 10 (5) :561-568.

[10]Liu C, Jiang CM, Liu CH, et al.Effect of Fuzhenghuayu de-coction on vascular endothelial growth factor secretion in he-patic stellate cells[J].Hepatobiliary Pancreat Dis Int, 2002, 1 (2) :207-210.

[11]Kon K, Ikejima K, Hirose M, et al.Pioglitazone prevents ear-ly phase hepatic fibrogenesis caused by carbon retrachloride[J].Biochem Res Commun, 2002, 29 (1) :55-61.

[12]Nan Y, Wang R, Zhao S, et al.Heme oxygenase-1 pre-vents non-alcoholic steatohepatitis through suppressinghepatocyte apoptosis in mice[J].Lipids Health Dis, 2010, 9:124.

[13]Wang RQ, Nan YM, Wu WJ, et al.Induction of heme oxy-genase-1 protects against nutritional fibrosing steatohepati-tis in mice[J].Lipids Health Dis, 2011, 10:31.

[14]Wu XL, Zeng WZ, Jiang MD, et al.Research progress insignal transduction pathway of liver fibrosis[J].World ChinJ Dig, 2006, 14 (22) :2223-2228. (in Chinese) 吴晓玲, 曾维政, 蒋明德, 等.肝纤维化的信号转导通路[J].世界华人消化杂志, 2006, 14 (22) :2223-2228.

[15]Friedman SL.Hepatic stellate cells:protean, multifunction-al, and enigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172.

[16]An DM, Ji G, Xing LJ, et al.Relationship between uroki-nase plasminogen activator and liver cirrhosis[J].WorldChin J Dig, 2006, 14 (21) :2106-2111. (in Chinese) 安德明, 季光, 邢练军, 等.uPA纤溶途径与肝纤维化[J].世界华人消化杂志, 2006, 14 (21) :2106-2111.

[17]Liu CH, Liu P, Hu YY, et al.Effects of salvianolic acid-A onrat hepatic stellate cell proliferation and collagen production inculture[J].Acta Pharmacol Sin, 2000, 21 (8) :721-726.

[18]Liu P, Liu CH, Wang HN, et al.Effect of salvianolic acid Bon collagen production and mitogen-activated protein kinaseactivity in rat hepatic stellate cells[J].Acta Pharmacol Sin, 2002, 23 (8) :733-738.

[19]Ji G, Wang L, Zhang SH, et al.Effect of chinese medicineQinggan Huoxuefang on inducing HSC apoptosis in alcoholicliver fibrosis rats[J].World J Gastroenterol, 2006, 12 (13) :2047-2052.

[20]Guo SG, Zhang W, Jiang T, et al.Influnence of serum col-lected from rat perfused with compound Biejiaruangan drugon hepatic stellate cells[J].World J Gastroenterol, 2004, 10 (10) :1487-1494.

[21]Yao L, Yao ZM, Weng H, et al.Effect of rat serum contai-ning Biejiajian oral liquid on proliferation of rat hepatic stellatecells[J].World J Gastroenterol, 2004, 10 (13) :1911-1913.

[22]Shen B, Yu J, Wang S, et al.Phyllanthus urinaria amelio-rates the severity of nutritional steatohepatitis both In vitroand in vivo[J].Hepatology, 2008, 47 (2) :473-483.

[23]Lian J, Lv ZS, Wang XL.Study on the prevention of nonal-coholic steatohepatitis with fibrosis by Ruangan compound[J].Chin J Integra Tradit West Med Liver Dis, 2008, 18 (3) :164-166. (in Chinese) 连佳, 吕宗舜, 王绪林.软肝煎对非酒精性脂肪肝大鼠肝纤维化的预防作用[J].中西医结合肝病杂志, 2008, 18 (3) :164-166.

[24]Shen L, Dou AX, Pan H, et al.Experimental study of treat-ment of nonalcoholic fatty liver disease with chitosan in rats[J].Chin Hepatol, 2009, 14 (1) :20-22. (in Chinese) 沈镭, 窦爱霞, 潘浩, 等.壳聚糖治疗大鼠非酒精性脂肪性肝病的初步试验研究[J].肝脏, 2009, 14 (1) :20-22.

[25]Lou SY, Liu Y, Ma YY, et al.Effects of Yiqi Sanju Formulaon non-alcoholic fatty liver disease:a randomized controlledtrial[J].J Chin Integr Med, 2008, 6 (8) :793-798. (inChinese) 娄少颖, 刘毅, 马宇滢, 等.益气散聚方治疗非酒精性脂肪性肝病随机对照临床试验[J].中西医结合学报, 2008, 6 (8) :793-798.

[26] Gu S, Huang MX.Clinical observation of Qianggan capsule inthe treatment of non-alcoholic fatty liver fibrosis[J].ChinJ Hepatol, 2011, 19 (10) :791-792. (in Chinese) 古赛, 黄秒兴.强肝胶囊治疗非酒精性脂肪性肝纤维化的疗效[J].中华肝脏病杂志, 2011, 19 (10) :791-792.

[27]Liu P, Mu YP, Liu CH.Clinical and basic progress of tradi-tional Chinese medicine in chronic liver disease[J].J ClinHepatol, 2011, 27 (5) :451-457. (in Chinese) 刘平, 慕永平, 刘成海.中医治疗慢性肝病的临床与基础研究进展[J].临床肝胆病杂志, 2011, 27 (5) :451-457.

施引文献

资源附件(0)

访问统计